# Vertex Pharmaceuticals (VRTX) P/B ratio: 7.4× today

URL: https://funkfolio.com/stock/VRTX/pb-ratio

> Vertex Pharmaceuticals (VRTX) P/B ratio is 7.4× today, against 6.3× at the end of fiscal 2025. Its median over 18 fiscal year-ends is 9.2×.

---

## Vertex Pharmaceuticals (VRTX) P/B ratio

**P/B ratio today:** 7.4× as of Nov 18, 2026, 6:21 AM UTC

Vertex Pharmaceuticals (VRTX) trades at 7.4× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 6.3×. That is 1.0% lower than the 6.3× of fiscal 2024. Figures as of 18 Nov 2026, 06:21 UTC, from the company's filings with the SEC and Yahoo Finance.

### Key facts

- **P/B ratio today:** 7.4×
- **P/B ratio, fiscal 2025:** 6.3×
- **Change on fiscal 2024:** −1.0%
- **Highest on record:** 32.3× fiscal 2015
- **Lowest on record:** 5.4× fiscal 2022
- **Fiscal years on record:** 18 2008–2025

Figures as of 18 Nov 2026, 06:21 UTC. Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

### Vertex Pharmaceuticals P/B ratio, in more detail

Today's figure is 17.8% above the fiscal 2025 year-end.

Across the 18 fiscal year-ends on record (2008–2025), the highest was 32.3× in fiscal 2015 and the lowest 5.4× in fiscal 2022. Today's P/B ratio is higher than at 39% of the 18 fiscal year-ends on record; their median is 9.2×.

### P/B ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

### Vertex Pharmaceuticals P/B ratio, year by year

Vertex Pharmaceuticals (VRTX) P/B ratio by fiscal year

| Fiscal year | P/B ratio | Change | Year ended | Share price at year-end | Book value per share |
| --- | --- | --- | --- | --- | --- |
| Today | 7.4× | — | Nov 18, 2026 | $534.20 | — |
| 2025 | 6.3× | 1.0% down | Dec 31, 2025 | $453.36 | $72.35 |
| 2024 | 6.3× | 5.0% up | Dec 31, 2024 | $402.70 | $63.63 |
| 2023 | 6.0× | 12.1% up | Dec 31, 2023 | $406.89 | $67.49 |
| 2022 | 5.4× | 4.8% down | Dec 31, 2022 | $288.78 | $53.70 |
| 2021 | 5.7× | 21.1% down | Dec 31, 2021 | $219.60 | $38.86 |
| 2020 | 7.2× | 23.6% down | Dec 31, 2020 | $236.34 | $32.98 |
| 2019 | 9.4× | 3.1% down | Dec 31, 2019 | $218.95 | $23.34 |
| 2018 | 9.7× | 48.2% down | Dec 31, 2018 | $165.71 | $17.11 |
| 2017 | 18.7× | 20.0% up | Dec 31, 2017 | $149.86 | $8.01 |
| 2016 | 15.6× | 51.8% down | Dec 31, 2016 | $73.67 | $4.73 |
| 2015 | 32.3× | 24.2% up | Dec 31, 2015 | $125.83 | $3.90 |
| 2014 | 26.0× | 111.1% up | Dec 31, 2014 | $118.80 | $4.57 |
| 2013 | 12.3× | 36.5% up | Dec 31, 2013 | $74.30 | $6.03 |
| 2012 | 9.0× | 2.4% up | Dec 31, 2012 | $41.90 | $4.64 |
| 2011 | 8.8× | 36.7% down | Dec 31, 2011 | $33.21 | $3.77 |
| 2010 | 13.9× | 105.7% up | Dec 31, 2010 | $35.03 | $2.51 |
| 2009 | 6.8× | 62.1% down | Dec 31, 2009 | $42.85 | $6.33 |
| 2008 | 17.9× | — | Dec 31, 2008 | $30.38 | $1.70 |

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

### How it is calculated

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.

### How to read it

It compares the price with the accounting value of what the company owns net of what it owes, and matters most for banks, insurers and other balance-sheet businesses.

### P/B ratio at health care companies of similar size

P/B ratio of Vertex Pharmaceuticals and comparable companies

| Company | P/B ratio |
| --- | --- |
| [Pfizer PFE](https://funkfolio.com/stock/PFE/pb-ratio) | 1.9× |
| [Danaher DHR](https://funkfolio.com/stock/DHR/pb-ratio) | 3.0× |
| [Intuitive Surgical ISRG](https://funkfolio.com/stock/ISRG/pb-ratio) | 8.4× |
| Vertex Pharmaceuticals VRTX | 7.3× |
| [Medtronic MDT](https://funkfolio.com/stock/MDT/pb-ratio) | 2.6× |
| [Bristol-Myers Squibb BMY](https://funkfolio.com/stock/BMY/pb-ratio) | 6.8× |

Today's market value divided by shareholders' equity at the latest fiscal year-end. A company whose statements are in another currency than its shares is left out.

### Vertex Pharmaceuticals, figure by figure

- [Vertex Pharmaceuticals market cap](https://funkfolio.com/stock/VRTX/market-cap)
- [Vertex Pharmaceuticals revenue](https://funkfolio.com/stock/VRTX/revenue)
- [Vertex Pharmaceuticals earnings](https://funkfolio.com/stock/VRTX/earnings)
- [Vertex Pharmaceuticals earnings per share (EPS)](https://funkfolio.com/stock/VRTX/eps)
- [Vertex Pharmaceuticals P/E ratio](https://funkfolio.com/stock/VRTX/pe-ratio)
- [Vertex Pharmaceuticals P/S ratio](https://funkfolio.com/stock/VRTX/ps-ratio)
- [Vertex Pharmaceuticals free cash flow](https://funkfolio.com/stock/VRTX/free-cash-flow)
- [Vertex Pharmaceuticals operating margin](https://funkfolio.com/stock/VRTX/operating-margin)
- [Vertex Pharmaceuticals dividend](https://funkfolio.com/stock/VRTX/dividend)
- [Vertex Pharmaceuticals shares outstanding](https://funkfolio.com/stock/VRTX/shares-outstanding)
- [Vertex Pharmaceuticals total debt](https://funkfolio.com/stock/VRTX/total-debt)
- [Vertex Pharmaceuticals cash on hand](https://funkfolio.com/stock/VRTX/cash)
- [Vertex Pharmaceuticals total assets](https://funkfolio.com/stock/VRTX/total-assets)
- [Vertex Pharmaceuticals return on equity (ROE)](https://funkfolio.com/stock/VRTX/roe)
- [Vertex Pharmaceuticals return on invested capital (ROIC)](https://funkfolio.com/stock/VRTX/roic)

[Vertex Pharmaceuticals (VRTX) overview: price, valuation and scorecard](https://funkfolio.com/stock/VRTX) [All health care companies by market value](https://funkfolio.com/companies/sector/health-care)

### Vertex Pharmaceuticals P/B ratio: questions and answers

**What is Vertex Pharmaceuticals's P/B ratio?**

Vertex Pharmaceuticals (VRTX) trades at 7.4× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 6.3×. That is 1.0% lower than the 6.3× of fiscal 2024.

**Is Vertex Pharmaceuticals's P/B ratio high or low compared with its own history?**

Today's P/B ratio is higher than at 39% of the 18 fiscal year-ends on record; their median is 9.2×.

**What are the highest and lowest P/B ratio figures on record for Vertex Pharmaceuticals?**

Across the 18 fiscal year-ends on record (2008–2025), the highest was 32.3× in fiscal 2015 and the lowest 5.4× in fiscal 2022.

**How is Vertex Pharmaceuticals's P/B ratio calculated?**

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

### Learn: P/B ratio

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [P/E ratio explained: what a high or low figure means](https://funkfolio.com/learn/stocks/pe-ratio)

  The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- [Piotroski F-score: the nine tests and what they show](https://funkfolio.com/learn/stocks/piotroski-f-score)

  The Piotroski F-score is a 0–9 count of simple accounting tests a company passes: four on profitability, three on debt, liquidity and share issuance, two on operating efficiency. Joseph Piotroski's 2000 paper found that among cheap, high book-to-market stocks, high scorers went on to beat low scorers. It is a screen of financial health, not a valuation.
- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.

### Cite this page

Funkfolio, “Vertex Pharmaceuticals (VRTX) P/B ratio”, data as of 18 November 2026. https://funkfolio.com/stock/VRTX/pb-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.
